Morphine promotes cancer stem cell properties, contributing to chemoresistance in breast cancer.

Dong-Ge Niu,Fei Peng,Wei Zhang,Zhong Guan,Hai-Dong Zhao,Jing-Lin Li,Kai-Li Wang,Ting-Ting Li,Yan Zhang,Fei-Meng Zheng,Fan Xu,Qian-Ni Han,Peng Gao,Qing-Ping Wen,Quentin Liu
DOI: https://doi.org/10.18632/oncotarget.2894
2015-01-01
Oncotarget
Abstract:Morphine is an opioid analgesic drug commonly used for pain relief in cancer patients. Here, we report that morphine enhances the mammosphere forming capacity and increases the expression of stemness-related transcription factors Oct4, Sox2 and Nanog. Treatment with morphine leads to enrichment of a side population fraction in MCF-7 cells and the CD44+/CD24(-/low) population in BT549 cells. Consistently, morphine activates Wnt/β-catenin signaling to induce epithelial to mesenchymal transition and promotes metastasis. Moreover, morphine decreases the sensitivity of traditional anti-cancer drugs in breast cancer cells. Nalmefene, an antagonist of morphine, reverses morphine-induced cancer stem cell properties and chemoresistance in breast cancer. In addition, nalmefene abolishes morphine enhancing tumorigenesis in a NOD/SCID mouse model. In conclusion, our findings demonstrate that morphine contributes to chemoresistance via expanding the population of cancer stem cells and promotes tumor growth, thereby revealing a novel role of morphine and providing some new guides in clinical use of morphine.
What problem does this paper attempt to address?